MDA-7 promoted liver cancer cell apoptosis and inhibited cell proliferation; while no effect was exerted on normal liver cells, as determined by the MTT assay and flow cytometry.
These results indicate that co-administration of Ad•enAFP•D55-(IL-24) and Ad•enAFP•D55-(SOCS3) may serve as a candidate therapeutic approach for the treatment of liver cancer.